{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:20:54Z","timestamp":1791980454362,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtho.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:27:13Z","timestamp":1739186833000},"page":"969-982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I\/II LUPER Study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-1947","authenticated-orcid":false,"given":"Antonio","family":"Calles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Gaston","family":"Doger de Speville Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric \u00c1lvarez","family":"Colom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Arregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramon-Patino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Corral de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcal\u00e1-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Fern\u00e1ndez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rodr\u00edguez-Morat\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Palmero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.02.005_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtho.2025.02.005_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib3","first-page":"620","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2025.02.005_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lungcan.2019.03.028","article-title":"Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017","volume":"131","author":"Lattuca-Truc","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.02.005_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib10","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.02.005_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.02.005_bib12","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, Phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A randomized non-comparative Phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1535-7163.MCT-24-0050","article-title":"Unveiling the mechanism of Lurbinectedin's action and its potential in combination therapies in small cell lung cancer","volume":"24","author":"Calles","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2025.02.005_bib17","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Santamar\u00eda Nu\u00f1ez","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2025.02.005_bib18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.02.005_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2014.01.005","article-title":"Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?","volume":"346","author":"Bowden","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtho.2025.02.005_bib20","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1093\/nar\/gky764","article-title":"Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage","volume":"46","author":"Slyskova","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2025.02.005_bib21","doi-asserted-by":"crossref","first-page":"9248","DOI":"10.3390\/ijms21239248","article-title":"Role of nucleotide excision repair in cisplatin resistance","volume":"21","author":"Duan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2025.02.005_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib24","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.02.005_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (Atlantis): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2025.02.005_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8524","article-title":"Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 Atlantis trial","volume":"40","author":"Navarro","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","author":"Hryniuk","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","article-title":"Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma","volume":"77","author":"Wildiers","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2025.02.005_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00280-021-04366-3","article-title":"Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer","volume":"89","author":"Fern\u00e1ndez-Teruel","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtho.2025.02.005_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40262-018-0701-2","article-title":"Population-pharmacokinetic and covariate analysis of lurbinectedin (PM01183), a new RNA polymerase II inhibitor, in pooled Phase I\/II trials in patients with cancer","volume":"58","author":"Fernandez-Teruel","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtho.2025.02.005_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107448","article-title":"Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval \u226530 days and without central nervous metastases","volume":"188","author":"Peters","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.02.005_bib32","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/curroncol31030126","article-title":"Outcomes of patients with non-small cell lung cancer and brain metastases treated with the upfront single agent pembrolizumab: a retrospective and multicentric study of the ESCKEYP GFPC cohort","volume":"31","author":"Nannini","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib33","article-title":"Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158","volume":"36","author":"Chung","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","article-title":"A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer","volume":"7","author":"Owonikoko","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","article-title":"IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets","volume":"41","author":"Unver","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jtho.2025.02.005_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593810","article-title":"Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer","volume":"8","author":"Hardy-Werbin","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jtho.2025.02.005_bib37","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.02.005_bib38","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2024.09.057","article-title":"OA10.03 Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up","volume":"19","author":"Sands","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113259","article-title":"Pooled safety analysis of single-agent lurbinectedin in patients with advanced solid tumours","volume":"192","author":"Leary","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.02.005_bib40","first-page":"A493","article-title":"464 2SMALL (NCT04253145) phase I part: lurbinectidinein (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)","volume":"9","author":"Aix","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2025.02.005_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8604","article-title":"MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy","volume":"40","author":"Leventakos","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib46","doi-asserted-by":"crossref","first-page":"S532","DOI":"10.1016\/j.jtho.2022.07.951","article-title":"EP14.01-015 IMforte: A Phase III study of Lurbinectedin and Atezolizumab versus Atezolizumab as maintenance therapy in ES-SCLC","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.02.005_bib47","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic therapy for small-cell lung cancer: ASCO-Ontario health (cancer care Ontario) guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:28:17Z","timestamp":1762550897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1556086425000644"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.02.005","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I\/II LUPER Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}